ST Pharm Presents Phase 1 Clinical Trial Results of HIV Treatment Candidate at AIDS 2022
(Adnkronos) - - STP0404 is the only clinical safety proven HIV treatment candidate with a novel mechanism that can block HIV re-activation.
- STP0404 is expected to enter Phase 2a clinical trial in the US in 4Q 2022.
SEOUL, South Korea, Aug. 3, 2022 /PRNewswire/ -- ST Pharm Co., Ltd.